Biocon launches Liraglutide products in Netherlands, expands GLP-1 portfolio

Biocon Limited, an innovation-led global biopharmaceutical company, announced on December 15, 2025, the launch of its GLP-1 peptide, Liraglutide, in the Netherlands. Marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management, this marks the first country in the European Union where Biocon will directly launch Liraglutide under its own brand. The launch follows approval from the Medicines Evaluation Board (MEB) in the Netherlands, with distribution handled by Pharmamedic B.V.

Siddharth Mittal, chief executive and managing director of Biocon Limited, highlighted the strategic importance of this launch, emphasizing its role in expanding Biocon's GLP-1 portfolio across key global markets and reinforcing the company's commitment to peptide-based therapies. He noted that the launch underscores Biocon's scientific and manufacturing excellence and its long-standing commitment to broadening access to advanced therapies for diabetes and obesity, contributing to more sustainable healthcare systems.

Liraglutide, a synthetic analog of the GLP-1 peptide, is administered as a once-daily injection. It was initially approved for medical use in the European Union in 2009 and by the US FDA in 2010. Further approvals in 2014 and 2015 extended its use for adults with obesity or overweight conditions, and in 2019, the US FDA approved it for children aged ten and older with type 2 diabetes.